In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
New leadership team announced at NATHEALTH Annual General Meeting 2024
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
Highlights the need for rebuilding, restructuring, and re-imagining resilient healthcare systems in India
A staggering 65% of the TB cases in India are in the 15-45 age group
He was earlier associated with leading industry players like Hindustan Unilever, TATA Communications, Dr. Lal Path Labs, Oncquest and Metropolis Healthcare
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)